Nur Aizati Athirah Daud

Dr. Nur Aizati Athirah Daud

School of Pharmaceutical Sciences, Universiti Sains Malaysia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MAMohammed Ahmed Akkaif
Mohammed Ahmed Akkaif
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban
MNMei li Ng
Mei li Ng
MKMuhamad Ali Sk Abdul Kader
Muhamad Ali Sk Abdul Kader
BIBaharudin Ibrahim
Baharudin Ibrahim
Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore reduce stent thrombosis. However, some patients still have ischemic events despite taking the clopidogrel due to the alteration in clopidogrel metabolism attributable to various genetic and non-genetic factors. This review aims to summarise the mechanisms and causes of clopidogrel resistance (CR) and potential strategies to overcome it. This review summarised the possible effects of genetic polymorphism on CR among the Asian population, especially CYP2C19 *2 / *3 / *17, where the prevalence rate among Asians was 23.00%, 4.61%, 15.18%, respectively. The review also studied the effects of other factors and appropriate strategies used to overcome CR. Generally, CR among the Asian population was estimated at 17.2–81.6%. Therefore, our overview provides valuable insight into the causes of RC. In conclusion, understanding the prevalence of drug metabolism-related genetic polymorphism, especially CYP2C19 alleles, will enhance clinical understanding of racial differences in drug reactions, contributing to the development of personalised medicine in Asia.

9 February 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
AAAdila Awaludin
Adila Awaludin
CRCherry Rahayu
Cherry Rahayu
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
NZNeily Zakiyah
Neily Zakiyah
Background: Hypertension in pregnancy causes significant maternal and fetal mortality and morbidity. A comprehensive assessment of the effectiveness of antihypertensive drugs for severe hypertension during pregnancy is needed to make informed decisions in clinical practice. This systematic review aimed to assess the efficacy and safety of antihypertensive drugs in severe hypertension during pregnancy. Methods: A systematic review using the electronic databases MEDLINE (PubMed) and Cochrane Library was performed until August 2021. The risk-of-bias 2 tool was used to assess the risk-of-bias in each study included. Meta-analysis was conducted to assess heterogeneity and to estimate the pooled effects size. Results: Seventeen studies fulfilled the inclusion criteria and 11 were included in the meta-analysis. Nifedipine was estimated to have a low risk in persistent hypertension compared to hydralazine (RR 0.40, 95% CI 0.23–0.71) and labetalol (RR 0.71, 95% CI 0.52–0.97). Dihydralazine was associated with a lower risk of persistent hypertension than ketanserin (RR 5.26, 95% CI 2.01–13.76). No difference was found in the risk of maternal hypotension, maternal and fetal outcomes, and adverse effects between antihypertensive drugs, except for dihydralazine, which was associated with more adverse effects than ketanserin. Conclusions: Several drugs can be used to treat severe hypertension in pregnancy, including oral/sublingual nifedipine, IV/oral labetalol, oral methyldopa, IV hydralazine, IV dihydralazine, IV ketanserin, IV nicardipine, IV urapidil, and IV diazoxide. In addition, nifedipine may be preferred as the first-line agent. There was no difference in the risk of maternal hypotension, maternal and fetal outcomes, and adverse effects between the drugs, except for adverse effects in IV dihydralazine and IV ketanserin.

29 May 2015 in Drug Safety
Verified
Journal Article
Open access
PDF file
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
JBJorieke E. H. Bergman
Jorieke E. H. Bergman
MBMarian K. Bakker
Marian K. Bakker
HWHao Wang
Hao Wang
WKWilhelmina S. Kerstjens-Frederikse
Wilhelmina S. Kerstjens-Frederikse
BWBob Wilffert
Bob Wilffert
Drug use in pregnancy is very common but may cause harm to the fetus. The teratogenic effect of a drug is partly dependent on the drug level in the fetal circulation, which is associated with the transport across the placenta. Many drugs are substrates of P-glycoprotein (P-gp), an efflux transporter that acts as a protective barrier for the fetus. We aim to identify whether drug interactions associated with P-gp promote any changes in fetal drug exposure, as measured by the risk of having children with congenital anomalies.

20 July 2021 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
MAMohammed Ahmed Akkaif
Mohammed Ahmed Akkaif
MNMei li Ng
Mei li Ng
MKMuhamad Ali Sk Abdul Kader
Muhamad Ali Sk Abdul Kader
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban
BIBaharudin Ibrahim
Baharudin Ibrahim

13 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
JBJorieke E H Bergman
Jorieke E H Bergman
MOMonika P Oktora
Monika P Oktora
WKWilhelmina S Kerstjens-Frederikse
Wilhelmina S Kerstjens-Frederikse
HGHenk Groen
Henk Groen
BWBob Wilffert
Bob Wilffert
A number of transporter proteins are expressed in the placenta, and they facilitate the placental transfer of drugs. The inhibition of P-glycoprotein (P-gp) was previously found to be associated with an increase in the risk of congenital anomalies caused by drug substrates of this transporter. We now explore the role of other placental transporter proteins. A population-based case-referent study was performed using cases with congenital anomalies (N = 5,131) from EUROCAT Northern Netherlands, a registry of congenital anomalies. The referent population (N = 31,055) was selected from the pregnancy IADB.nl, a pharmacy prescription database. Ten placental transporters known to have comparable expression levels in the placenta to that of P-gp, were selected in this study. In total, 147 drugs were identified to be substrates, inhibitors or inducers, of these transporters. Fifty-eight of these drugs were used by at least one mother in our cases or referent population, and 28 were used in both. The highest user rate was observed for the substrates of multidrug resistance-associated protein 1, mainly folic acid (6% of cases, 8% of referents), and breast cancer resistance protein, mainly nitrofurantoin (2.3% of cases, 2.9% of referents). In contrast to P-gp, drug interactions involving substrates of these transporters did not have a significant effect on the risk of congenital anomalies. Some of the drugs which are substrates or inhibitors of placental transporters were commonly used during pregnancy. No significant effect of transporter inhibition was found on fetal drug exposure, possibly due to a limited number of exposures.

1 May 2014 in Pharmacogenomics
Verified
Journal Article
Closed access
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
JBJorieke Eh Bergman
Jorieke Eh Bergman
MBMarian K Bakker
Marian K Bakker
HWHao Wang
Hao Wang
HWHermien Ek de Walle
Hermien Ek de Walle
BWBob Wilffert
Bob Wilffert
One of the ongoing issues in perinatal medicine is the risk of birth defects associated with maternal drug use. The teratogenic effect of a drug depends, apart from other factors, on the exposition of the fetus to the drug. Transporter proteins are known to be involved in the pharmacokinetics of drugs and have an effect on drug level and fetal drug exposure. This condition may subsequently alter the risk of teratogenicity, which occurs in a dose-dependent manner. This review focuses on the clinically important polymorphisms of transporter proteins and their effects on the mRNA and protein expression in placental tissue. We also propose a novel approach on how the different genotypes of the polymorphism can be translated into phenotypes to facilitate genetic association studies. The last section looks into the recent studies exploring the association between P-glycoprotein polymorphisms and the risk of fetal birth defects associated with medication use during pregnancy.